Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 40

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 40
---
                        | 1,452,750 |   |     |                                                                   |     |       — |     |   |                                       |          — |   |
| Javier San Martin    |     |       |     | 01/04/2024 |     |                                 | — |        |     |                        |         — |   |     |                                                                   |     |       — |     |   |                                       |            | — |
| Tracie Oliver        |     |       |     | 07/01/2022 |     |                                 |   | 35,000 |     |                        |   677,950 |   |     |                                                                   |     |       — |     | — |                                       |            | — |
|                      |     |       |     | 01/04/2023 |     |                                 |   |    375 |     |                        |     7,264 |   |     |                                                                   |     |       — |     | — |                                       |            | — |
|                      |     |       |     | 01/04/2024 |     |                                 |   | 75,000 |     |                        | 1,452,750 |   |     |                                                                   |     |       — |     | — |                                       |            | — |

(1) RSUs have various vesting parameters but generally vest in four equal annual installments beginning one year from the grant date.

(2) Value is based on our Company’s Common Stock closing price of $19.37 on September 30, 2024.

(3) The amounts reported for Christopher Anzalone in this column reflect the January 2020, January 2021, July 2022, December 2022, and December 2023 awards that contain performance-based vesting conditions. These awards and their vesting conditions are described above in the “Compensation Discussion and Analysis” under the heading “Equity Compensation” and in prior proxy statements, as applicable.

Fiscal 2024 Options Exercises and Stock Vested Table

The following table provides information, with respect to the NEOs, concerning options exercised or RSUs or PRSUs vested during fiscal 2024.

| Name                 |     | Option Awards                       
 Number of SharesAcquired onExercise |     |        |     |   | Value Realized on 
 Exercise (1)      |           |   |     |   | Stock Awards     
 Number of Shares 
 Acquired on      
 Vesting          |     |